Cargando…
Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature
Gemcitabine is an antineoplastic used to treat several malignancies including pancreatic cancer. Its toxicity profile is well known with myelotoxicity, increased vascular permeability and peripheral oedema as most frequent adverse events. However, several cases of acute renal failure have been repor...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212612/ https://www.ncbi.nlm.nih.gov/pubmed/30397609 http://dx.doi.org/10.12998/wjcc.v6.i12.531 |